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INTRODUCTION are caused by multiple factors such as accumulation
Mounting prevalence of end-stage renal disease of uremic toxins, volume overload, effects of
(ESRD) is a major public health problem worldwide, dialysis equipment and techniques such as needle
with millions of individuals affected. These patients insertion and subcutaneous bleeding during
suffer from a multitude of symptoms with very dialysis treatment, metabolic and immunologic
low quality of life, accompanied by a particularly derangements, nutritional factors, and side effects
high prevalence of dermatologic disorders. It is of drugs.6 Early recognition and treatment of skin
interesting to note that about between 50% to 100% changes can relieve the associated suffering and
of patients with ESRD have at least 1 dermatological perhaps could also provide some cure or at least
disorder (Figure 1).1,2 reduce the adverse outcomes, which may improve
Cutaneous disorders may range from benign to quality of life in these patients.7 The cutaneous
life-threatening conditions, sometimes representing changes may appear any time throughout the course 
the earliest sign of kidney disease.3 Chronic kidney of kidney disease occurring from the beginning to
disease is associated with dysfunction of multiple the progression to the terminal stage.3 However,
organ systems, including the skin which serves majority of patients become more symptomatic in
as an important diagnostic window to various the advanced stages of the disease. 
systemic diseases.1,3,4 It has been suggested that T h e  c o m m o n l y  r e p o r t e d  c u t a n e o u s  
dermatological disorders are related to the duration abnormalities include pruritus, xerosis, cutaneous
and severity of kidney disease, many of which are hyperpigmentation, and half and half nails 
exacerbated by hemodialysis therapy rendering as well as Meurcki lines, which are relatively
these patients a poor quality of life.5 benign as compared to more serious conditions
From the pathophysiologic point, these changes of perforating disorders, calcifying disorders, and
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Figure 1. Dermatologic findings in end-stage renal disease. 
bullous dermatoses, carrying significant morbidity.8 
Each manifestation presents with unique clinical
features. We focus on commonly encountered
cutaneous entities of kidney failure and classify
them according to their pathophysiology. 
PRURITUS AND XEROSIS 
Clinical Presentation 
Pruritus is the most frequent cutaneous symptom
of ESRD, experienced by 58% to 90% of patients
undergoing maintenance dialysis.2 It remains a
distressing problem for patients, causing serious
discomfort and skin damage, and it is often
associated with sleeping problems and diminished
quality of life.9,10 Pruritus can be localized or
generalized. The most frequently involved body
areas are the back, limbs, chest, and face.9 The
affected skin may either appear normal or exhibit
excoriations, lesions of lichen simplex chronicus,
prurigo nodularis, and keratosis papules.11 Skin
trauma due to pruritus might also contribute to
koebnerization of acquired perforating dermatosis.3 
Koebner reaction refers to the lesions which could
result from trauma or irritation of the skin. 
Pathophysiology 
A number of different mechanisms have been
proposed to explain the origin of pruritus. Xerosis
is a frequent skin problem (60% to 90%) in dialysis
patients that predisposes to pruritus (Figure 2).
Dryness of skin is caused by primary dermal
changes associated with uremia, such as atrophy
of sweat glands with impaired sweat secretion,
disturbed stratum corneum hydration, sebaceous
Figure 2. Xerosis in a dialysis patient (used with permission). 
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gland atrophy, and abnormal terminal branching of
free cutaneous nerve fiber endings.9 Male sex, old
age, high predialysis level of blood urea nitrogen,
and high levels of β2-microglobulin, calcium, and
phosphate are the risk factors for pruritus.11 The
other factors that may play a role include secondary
hyperparathyroidism, hypervitaminosis A, iron
deficiency anemia, abnormal levels of magnesium
and aluminum, as well as increased histamine and
mast cells.2,3 
There are 2 main hypotheses of the mechanisms
of pruritus. The opioid hypothesis suggests that the
overexpression of opioid μ receptors is responsible
for pruritus, which can be prevented by central
κ opioid receptor stimulation. This theory is
supported by successful treatment of patients with
opioid antagonists. On the other hand, the immune
hypothesis considers pruritus as a manifestation of
systemic inflammation as shown by higher levels
of pro-inflammatory mediators like C-reactive
protein and interleukin-6.9,10 Calcium-phosphorus
product which determines calcium phosphate
precipitation in the skin also has an important
role in pruritus. Side effects of some drugs such as
angiotensin-converting enzyme inhibitors and the
effect of some kinds of dialysis membrane could
be other causes of pruritus.11 
Treatment 
Treatment depends on the etiology of pruritus,
and it should be individualized according to
patient’s needs. For example, if it is due to
xerosis, skin moisturizing is the key of treatment.
Moisturizing of skin with topical lubricants
and keratolytics are, however, only of minimal
advantage despite the presence of xerosis.3 For
more localized areas of pruritus, the use of topical
corticosteroids, pramoxine hydrochloride, and
topical capsaicin cream (0.025%) is suggested.
The latter acts by depleting substance P from
cutaneous type C sensory nerve endings, which
activates μ opioid receptors leading to the itch.3,9,10,12 
Systemic medications including oral activated
charcoal, gabapentin, an anticonvulsant as well
as thalidomide, an immune modulator. These
have shown significant benefit in ameliorating the
pruritus symptoms, but their use is reserved for
the patients with therapy-resistant pruritus.13 Other
oral medications are nalfurafine, a κ opioid agonist,
ondansetron, a selective serotonin antagonist and
cholestyramine which have been reported to have
variable efficacy.9,10,14 
Based on the opioid theory, the use of naltrexone,
an opioid antagonist, has shown benefits in short-
term treatment of pruritus.11 Phototherapy with
ultraviolet B is effective in reducing pruritus in
dialysis patients.14 It is suggested that it acts by
suppressing histamine release as well as vitamin
A levels in the epidermis which are known 
pruritogenic substrates responsible for itching;
however, its potential for skin cancer should be
considered seriously.7,11 Besides these therapies,
it has been demonstrated that higher dialysis
quality, administration of erythropoietin, and a
good nutritional state also play a role in alleviating
pruritus in hemodialysis patients.10,14 Above all
these therapies the definitive cure for pruritus
remains kidney transplantation.12 
CALCINOSIS CUTIS 
Clinical Presentation 
Calcinosis cutis, a form of metastatic calcification,
refers to the deposition of insoluble calcium salts
into the skin and subcutaneous tissue and is
commonly seen in patients with chronic kidney
disease (Figure 3).15 In metastatic calcification,
there is precipitation of calcium salts in normal
tissue due to underlying abnormality of calcium
or phosphate metabolism.3 Calcinosis cutis occurs
in about 1% of patients with ESRD on maintenance
dialysis, annually.11 Clinically, it appears as yellow-
white adamant tumors characterized by papules,
plaques, and nodules of different sizes within
the skin.15 The most commonly involved sites
are peri-articular areas and finger tips.2,3,8 Peri-
Figure 3. Calcinosis cutis or benign nodular calcification 
(reprinted with permission. https://commons.wikimedia.org/wiki/ 
File:CREST2015.JPG). 
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articular lesions are usually painless unless joint
mobility is affected. However, fingertip lesions
are usually painful.2,8 A white chalky substance
may be expressed through the skin.11 
Histopathology shows homogenous blue material
(calcium) in the dermis and subcutis surrounded
by foreign body giant cells and inflammation.2,8 
Pathophysiology 
In chronic kidney disease, calcification of the skin
occurs due to secondary hyperparathyroidism,7 which
results from hyperphosphatemia and hypocalcaemia.
In kidney disease hyperphosphatemia, results from
decreased excretion of phosphorus. Hypocalcaemia
is the result of decreased intestinal absorption of
calcium due to impaired synthesis of active form
of vitamin D. The resultant hyperparathyroidism
in patients suffering ESRD causes mobilization
of calcium and phosphorus from bone into 
serum, causing elevated levels of both calcium
and phosphorus as well as their products, which
contribute to development of lesions.2,11 
Treatment 
The focus of therapy is normalization of calcium
and phosphorus levels, as lesions will spontaneously
regress.8,10 This can be achieved by phosphate
binders and reduction of dietary phosphate.3 
Foods rich in phosphate contents include milk
and milk products, certain vegetables (broccoli
and Brussels sprouts), oysters, salmon, beer, nuts,
and wheat germ should be limited.10 In case of
secondary hyperparathyroidism, if calcimimetic
drugs such as cinacalcet are not effective, surgical
parathyroidectomy may allow for cure.11,15 
CUTANEOUS PIGMENTATION 
Clinical Presentation 
A range of skin color changes have been described
in chronic kidney disease patients undergoing
dialysis, including pallor (8%), yellowish tinge
(40%), and diffuse hyperpigmentation (22%) on
sun-exposed areas (Figure 4).16,17 These cutaneous
changes represent one of the most common markers
of kidney disease, seen relatively early during
the disease course.18 The pigmentary alteration
is reported to occur in 25% to 70% of dialysis
population and increases over the duration of
kidney disease.19 Although hyperpigmentation is
most frequently observed presentation of chronic
Figure 4. Brown dispegmentation seen on the sunexposed 
parts of the body (Reprinted with permission. https://commons. 
wikimedia.org/wiki/File:Skin_tanning.JPG). 
kidney disease, some cases of hypopigmentation
are described as well.20 
Pathophysiology 
Diffuse hyperpigmentation on sun-exposed areas
is due to an increase in melanin pigment in the basal
layer of epidermis and superficial dermis, which
results from an elevated levels of poorly dialyzable
beta-melanocyte–stimulating hormone.7,19 The
intensity of melanin pigmentation increases with
the duration of ESRD.17 More than 50% of patients
on long-term hemodialysis develop unusual forms
of hyperpigmentation.21 The yellowish (sallow) hue
is due to accumulation of lipid-soluble pigments
such as lipochromes and carotenoids which are
deposited in the dermis and the subcutaneous
tissue.7,17,19 Grayish-brown skin discoloration seen
in kidney disease is attributed to deposition of
hemosiderin.3,17 Pallor of the skin is secondary
to anemia of chronic disease and erythropoietin
deficiency as well as resistance and iron and folic
acid deficiency.3,21 
Treatment 
T h e  s u g g e s t e d  t r e a t m e n t  i s  t h e  u s e  o f  
hemodiafi l trat ion which clears the middle 
molecular-weight substances like urochrome
pigments ,  carotenoids ,  and β -melanocyte­
stimulating hormone more effectively than 
hemodialysis. Hemodiafiltration mechanism is
designed according to a combination of both
diffusive and convective filtrations; therefore, larger
solutes could be removed more effectively than
the regular hemodialysis.22 This leads to reduced
accumulation of pigments with consequent decrease
in hyperpigmentation. In addition, patients with
chronic kidney disease should be advised to use
Dermatologic Manifestations in End-stage Renal Disease—Shafiee et al
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sunscreen, wide brimmed hats, and sun protective
clothing to avoid pigment changes.11 
HALF AND HALF NAILS AND MUEHRCKE 
LINES 
Clinical Presentation 
Half and half nails, also known as Lindsay
nails, are the most common nail change seen in
patients with chronic kidney failure (Figure 5).3 
Several studies have reported its prevalence ranging
from 16% to 50.6%.4 Half and half nails have been
observed in one-third of patients with uremia
and is more characteristic of dialysis population
occurring in as many as 40% of patients.17,23 There
is no relationship between the severity of azotemia
and the intensity of discoloration.24 Clinically, nails
show a white to normal proximal half and a reddish
pink to brown distal half.7,18 The discoloration does
not disappear with pressure and is not affected
by nail growth, suggesting an abnormality in the
nail bed.11 Fingernails are affected more frequently
than toenails.24 
Nonpalpable  white  t ransverse  bands  of  
fingernails, known as Muehrcke lines, which do
not move with nail growth, could be a reversible
feature of hypoalbuminemia (Figure 6).25 
Pathophysiology 
The exact mechanism related to half and half
nails is not clear. The suggested hypotheses include
the elevated levels of β-melanocyte-stimulating
hormone, which leads to activation of melanocytes
with consequent deposition of melanin pigment in
the nail plate.17,20 Lindsay, after whom this condition
Figure 5. Half and half or Lindsay nails (reprinted with 
permission. http://stanfordmedicine25.stanford.edu/the25/hand. 
html). 
Figure 6. Muehrcke lines (reprinted with permission. http:// 
stanfordmedicine25.stanford.edu/the25/hand.html). 
is named, thought that the discoloration is caused
by constricted venous return from the nail bed.24,25 
Treatment 
The successful kidney transplantation may lead
to remission of half and half nails in some cases
but not the others.3,17 There is no improvement of
condition with dialysis therapy.11 
CALCIPHYLAXIS 
Clinical Presentation 
Calciphylaxis,  also called calcific uremic 
arteriolopathy, is a rare and often life-threatening
complication of ESRD.26 It occurs in both peritoneal
and hemodialysis patients and can sometimes
occur prior to dialysis.18,27 The reported incidence
rate is about 1% in patients with chronic kidney
disease and up to 4% in those on dialysis.13,18 
Risk factors for the development of calciphylaxis
include female sex, Caucasian race, obesity,
diabetes mellitus, malnutrition (low serum albumin
levels), and warfarin therapy (Table).13,28,29 Other
Risk Factors for Calciphylaxis 
Risk Factors 
Elevated parathyroid hormone levels 
Elevated calcium-phosphate product (≥ 17.5 mmol/L) 
Vitamin D 
Kidney failure 
Diabetes mellitus 
Female sex 
Obesity 
Caucasian 
Immunosuppression 
Lymphoma 
Human immunodeficiency virus 
Local trauma 
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factors associated with calciphylaxis are the
use of vitamin D analogs, calcium containing
phosphate binders, iron-replacement therapy, and
glucocorticosteroids.13,30 
Although calciphylaxis mainly occurs in patients
with chronic kidney disease, about 30% of cases
are reported in kidney transplant patients.3 Also,
it has been observed in patients with cancer,
human immunodeficiency virus infection, cirrhosis,
systemic lupus erythematosus, inflammatory bowel
disease, and primary hyperparathyroidism with
normal kidney function.8,30 
Clinically, patients initially develop superficial
v i o l a c e o u s  s k i n  l e s i o n s  t h a t  a r e  p a i n f u l ,  
hyperesthetic, or pruritic surrounded by pallor or
ecchymosis manifesting a livedo reticularis pattern.
This pattern refers to the changes in cutaneous blood 
flow, which produces bluish purple retinacular
hyperpigmentation on the skin.31 The initial
redness may evolve into intense erythema, which
over a period of days or weeks, transforms into
frank necrosis with eschar formation. Gangrenous
infection may thereafter develop at the site.
Subcutaneous nodules can often be felt extending
beyond the edges of obvious skin lesion.13,28,30 The
most common sites of involvement overlie thick
adipose tissue such as the breast, abdomen, and
thighs (Figure 7).10,12,32 Other less common locations
of calcific uremic arteriolopathy include the heart,
lung, pancreas, tongue, eye, and penis.28 Proximal
areas of necrosis (thighs, buttocks, and trunk) have
an unfavorable prognosis with a mortality rate of
60% to 80%, whereas acral distribution (calves,
forearms, fingers, toes, and penis) is associated
with 20% to 30% mortality rate.17,28 
Pathophysiology 
The pathophysiology of  calc iphylaxis  is  
multifactorial, because there is no single event
enough which can predict its development.9, 11 
Disturbance of phosphate and calcium homeostasis
in chronic kidney disease is a key factor that
under l ies  the  mechanism of  ca lc iphylaxis  
(Figure 8).9, 12 
With  the  progress ion of  k idney fa i lure ,  
elevated serum phosphorus levels, especially
postprandial, in addition to low serum calcium
levels secondary to impaired renal production
of 1,25-dihydroxycholecalciferol,  results in 
decreased intestinal calcium absorption, which
leads to secondary hyperparathyroidism and
hyperphosphatemia with consequent calcium
deposit ion in microvasculature and t issue 
ischemia.33 Although abnormalities of calcium,
phosphorus, and parathyroid metabolism are
implicated in the mechanism, high levels of
calcium-phosphate product are not always absolute
Figure 7. Calciphylaxis (used with permission). Figure 8. Pathophysiology of calciphylaxis 
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for the syndrome.2,3,10 Furthermore, it has been
suggested that an imbalance of inducers and
inhibitors of calcification of the vascular wall
leads to calciphylaxis.10,13 This is supported by
upregulation of inducers of vascular calcification,
including osteopontin expressed by vascular
smooth muscle cells and bone morphogenic protein
4 normally involved in bone development.8,12 
Additionally, there is transformation of vascular
smooth muscle cells into osteoblast-like cells with
the expression of bone-related proteins such as
osteocalcin, bone sialoprotein, type 1 collagen,
and osteopontin.13 Other mechanism thought
to be deranged is suppression of inhibitors of
vascular calcification including matrix Gla protein,
osteoprotegerin, pyrophosphate, and fetuin-A.9,10 
Matrix Gla protein requires vitamin-K–mediated
γ-carboxylation for its functional activity. As a result,
coumarin anticoagulants and vitamin K deficiency
may antagonize matrix Gla protein function and
stimulate vascular calcification.9 Levels of both
osteoprotegerin and fetuin-A decline (via the nuclear
factor κB cascade) by the inflammatory changes
encountered in uremia.9,13 Loss of pyrophosphate is
related to dialytic clearance along with decreased
synthesis and increased extra renal clearance,
which favors the tissue calcification in chronic
kidney disease.13 
It has been suggested that a hypercoagulable
state secondary to an absolute or functional
protein C or protein S deficiency may be involved
in the pathogenesis of calciphylaxis.9 In addition,
abnormal deposition, especially of aluminum and
certain microorganisms may have a role in the
pathogenesis of calciphylaxis.2,10 
Skin biopsy is a useful means of understanding the
pathophysiology of the disorder.31 Histologically,
calciphylaxis demonstrates medial wall calcification
of capillaries, venules, arterioles, and small arteries
of dermis and subcutaneous fat along with intimal
hyperplasia and endovascular fibrosis.30 Affected
vessels range in size from 0.02 mm to 0.60 mm
and an average of 0.1 mm.3 Calcification of dermal
vessels causes occlusion and subsequent tissue
ischemia as well as necrosis, hence named as calcific
uremic ischemic arteriolopathy.28,30 
A giant cell reaction may be observed in some
vessels. Endovascular thrombosis may occur in
subcutaneous and superficial dermal vessels but
is not a diagnostic feature of calciphylaxis.30 
Treatment 
Generally, therapeutic choices for calciphylaxis
are limited, basically supportive in nature with
unclear outcomes.34 The main focus of treatment is
to halt the progression of calcification and prevent
lethal complications.35,36 As the abnormality of
calcium phosphate metabolism has a vital role
in development of calciphylaxis in patients with
kidney failure, the primary treatment options
revolve around controlling calcium and phosphate
levels, which is achieved by using noncalcium-based
phosphate binders (eg, sevelamer hydrochloride
or lanthanum carbonate), increasing the frequency
of dialysis (with low calcium dialysate) as well as
proper use of vitamin D analogs, and limiting the
phosphate intake (43 mg/d).2,26,35 Also, preventing
secondary hyperparathyroidism and optimizing
nutritional state are equally important.28 In 
patients with elevated parathyroid hormone levels,
emergent parathyroidectomy is indicated, which
has shown survival advantage in short-term with
complete healing of ulcers within weeks after the
procedure.12,13,27 Parathyroidectomy is not useful
in patients with low parathyroid hormone levels
and may be harmful.3 For patients who cannot
undergo surgery, medical therapy with cinacalcet,
a calcimimetic is recommended, which increases
the sensitivity of calcium-sensing receptor on the
parathyroid glands.13,37 Furthermore, supportive
measures include meticulous wound care, which
may require frequent debridement of necrotic tissue, 
judicious use of systemic antibiotics to prevent
infection, and adequate opioid analgesia.12 In 
some cases, wound healing is improved by using
vacuum dressing.13 
A recent therapeutic approach includes the use of
sodium thiosulfate, an inorganic salt which chelates
calcium from soft tissue deposits to form calcium
thiosulfate, a highly soluble calcium salt.13,38,39,40 It 
also decreases the metastatic calcification in patients
with chronic kidney disease.12 In addition, it acts as
a potent antioxidant, which helps neutralize reactive
oxygen radicals by generating the antioxidant
glutathione.40 Also, it prompts endothelial nitric
oxide production thereby increases tissue blood flow
and oxygenation.12,13 Furthermore, it metabolizes
to hydrogen sulfide which has also vasodilatory
effects.39 Recommended treatment dosing is 5 g to
25g, 3 times per week at the end of each hemodialysis
session for about 2 weeks to 34 months.41 Although
Dermatologic Manifestations in End-stage Renal Disease—Shafiee et al
346 Iranian Journal of Kidney Diseases | Volume 9 | Number 5 | September 2015
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
       
 
 
 
  
 
    
 
 
 
 
 
 
 
 
      
 
it is considered safe, the main side effects include
nausea, vomiting, headache, rhinorrhea, and anion
gap metabolic acidosis.39 
Bisphosphonates, both intravenous and oral,
have also been used effectively in the treatment
of calciphylaxis, with reported improvement in
pain and signs of inflammation. The mechanism
of action of bisphosphonates is complex, but
it is thought to alter the ectopic deposition of
calcium phosphate, suppress pro-inflammatory
cytokines, and inhibit macrophage activity.12,13,28 
It acts as a direct inhibitor of calcification similar
to pyrophosphate.12 
Hyperbaric oxygen therapy has been proved
to be useful in treating calciphylaxis in patients
undergoing both peritoneal and hemodialysis.
Wounds that are refractory to medical management
could  respond to  parathyroidectomy and 
debridement.2 It enhances wound healing by
promoting oxygen delivery to the damaged tissues,
stimulating angiogenesis and collagen synthesis,
thereby improving neutrophil-mediated bacterial
killing, and reducing local tissue edema.2,12,13 
Moreover, patients with calciphylaxis should
be assessed for hypercoagulable states such as
proteins C and S and vitamin K deficiencies and
antiphospholipid syndrome and anticoagulated
accordingly.29 In patients with warfarin-associated
calciphylaxis, vitamin K therapy is recommended,
and in patients who require chronic warfarin
therapy, it should be switched to alternative
anticoagulants.13,29 
Other triggers which should be avoided include
obesity, local tissue trauma, and subcutaneous
injections.2, 9 
Prognosis 
The prognosis of calciphylaxis remains poor in
spite of aggressive therapeutic approaches, because
by the first time the clinical signs are obvious,
it is often too late to reverse the condition due
to underlying significant vasculopathy.9,30 The
vascular calcification increases the likelihood of
ischemic events resulting in higher cardiovascular
morbidity and mortality.33 
The mortality associated with this syndrome is
about 60% to 80%.3 Death mainly occurs due to
sepsis or even multisystem organ failure, which
is common within the months of diagnosis most
probably due to delayed diagnosis.31,36,42 Patients
with proximal necrosis have a more adverse outcome
compared to those with distal involvement.2,29 It 
is estimated that 1-year rate of survival is 45%
and the 5-year rate is 35%.13,40 An early clinical
diagnosis and intervention may improve the dismal
prognosis of condition.13 
ACQUIRED PERFORATING DISORDERS 
Clinical Presentation 
Acquired perforating disorders represent a
collection of diseases most commonly seen in the
setting of ESRD and diabetes mellitus.8,11 They have
also been reported in advanced chronic kidney
disease and kidney transplant recipients.12 The
estimated incidence of perforating disorders ranges
from 4.5% to 10% in hemodialysis population with
a predilection for African-American patients.17,22 
The characteristic diagnostic feature of condition is
extrusion of dermal material through an epidermal
channel (Figure 9).10 The acquired perforating
disorders have similar clinical and histologic
features to that of primary perforating disorders:
Kyrle disease, perforating folliculitis, reactive
perforating collagenosis, and elastosis perforans
serpiginosa.11 
Clinically, the skin lesions consist of clustered
dome-shaped papules, plaques, and nodules with
centralized keratotic plug, ranging in size from 2
mm to 8 mm.8,12 They are most commonly found in
areas susceptible to friction like extensor surfaces
of the extremities with hair bearing areas as well as
trunk being the most frequently involved followed
by the scalp and the face.8,18 The pruritus is usually
intense and the lesions may coalesce in a linear
fashion secondary to koebnerization.11 In white
skins, the lesions appear pink and in darker skins,
hyperpigmented or brown lesions are usually seen.3 
The skin lesions may resolve spontaneously with
the continued formation of new lesions.2 
Pathophysiology 
The pathophysiology of acquired perforating
disorders is not clear. Various theories have
been suggested to explain the development of
the condition.18 It may occur due to poor blood
supply secondary to vasculopathy in patients with
diabetes mellitus or kidney disease.11 Pruritus and
scratching-induced local injury leads to dermal
necrosis and inflammatory reaction, which is further
aggravated by dermal microdeposits of calcium
Dermatologic Manifestations in End-stage Renal Disease—Shafiee et al
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Figure 9. Acquired perforating disorders. A to C, Multiple excoriated hyperkeratotic papules and nodules with central crust involving 
the whole integument. D, Koebnerization (reprinted with permission. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365­
05962013000100094&lng=en&nrm=iso&tlng=en). 
and uric acid.2,13 A foreign body reaction to altered
dermal connective tissue is also thought to be a
causative factor in acquired perforating disorders.8 
It has been proposed that abnormal proliferation
of epidermis secondary to faulty metabolism of
vitamin A and D in kidney disease may play
a role in the pathogenesis of the condition.18 
Other factors responsible for the disease process
include elevated levels of fibronectin that acts as
a chemotactic substance for neutrophils and also
stimulates epithelial proliferation.18 Leukocytes
may also contribute to pathogenesis of perforating
disorders as indicated by the presence of nuclear
material in the eliminated product. It is believed that
elastase and collagenase, the proteinases released
from degenerating leukocytes, may modify dermal
connective tissue (Figure 10).2,18 
Treatment 
Since vasculopathy is the initial event, prevention
of vasculopathy is the key. Symptomatic or supportive
treatment of this disorder is often challenging with
Dermatologic Manifestations in End-stage Renal Disease—Shafiee et al
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Figure 10. Pathophysiology of acquired perforating disorders 
variable efficacy offered by numerous therapeutic
modalities.3 The options include potent topical
steroids, topical steroids under occlusion, and
intralesional steroids which may relieve the
inflammation but will not prevent the formation
of new lesions.8 Topical and systemic retinoids and
oral vitamin A (100 000 U/d) are beneficial in some
cases.8 Cryotherapy and keratolytics have been tried
with variable success.13 Narrowband ultraviolet
B phototherapy, psoralen plus ultraviolet A, and
allopurinol may also be considered in managing
acquired perforating disorders.11 
BULLOUS DERMATOSES 
Clinical Presentation 
There are 2 types of blistering disorders which
occur in patients with chronic kidney failure, being
treated with hemodialysis therapy: a true porphyria
(pophyria cutanea tarda) and pseudoporphyria
(dialysis-porphyria; Figures 11 and 12).9,18,43 
The reported prevalence of these disorders
in hemodialysis patients ranges from 1.2% to
18%.11 Porphyria cutanea tarda is associated with
abnormality of heme biosynthesis and caused
by deficiency of enzyme uroporphyrinogen 
decarboxylase.12 It  is classified as sporadic 
(acquired and type 1) and congenital (hereditary
and type 2) forms.3 In the acquired group, there
is enzymatic deficiency only in the liver, while
in congenital group, all the tissues are deficient
including erythrocytes and fibroblasts.3,8 Both
conditions share a similar clinical manifestation
and are characterized by a blistering photosensitive
skin rash.18 The skin lesions include tense vesicles
and bulla with a predilection for dorsal hands,
forearms, as well as face, with the feet rarely
involved.3,9 The crusting and erosions may develop
secondary to blister injury and healing of lesions
occur with scarring and milia formation.11 Besides,
facial hyperpigmentation and hypertrichosis of
sun-exposed skin are frequently observed.13 The 
sclerodermoid plaques have also been reported,
while in pseudoporphyria, patients do not manifest
hypertrichosis and scerodermoid changes.10,18 
The risk factors associated with porphyria
cutanea tarda include alcohol, iron, estrogens,
and viral infections including hepatitis B, hepatitis
C, and human immunodeficiency syndrome.3 
Pseudoporphyria is thought to be triggered by
certain medications like furosemide, naproxen,
amiodarone, tetracycline, nalidixic acid, and
excessive ultraviolet exposure.12 
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Figure 11. Porphyria cutanea tarda (reprinted with permission43). 
Figure 12. Dialysis porphyria (reprinted with permission43). 
Pathophysiology 
The pathophysiology of bullous disorders in
patients with kidney failure is not clear.10 Various
factors have been implicated in the mechanism of
porphyria cutanea tarda which include azotemia that
is thought to reduce the activity of uroporphyrinogen
decarboxylase involved in the metabolic pathway of
porphyrins.18 Another mechanism is poor clearance
of uroporphyrins in patients with kidney failure,
which results in higher plasma levels.12 Patients on
hemodialysis therapy may also develop porphyria
cutanea tarda as standard hemodialysis does not
effectively remove the uroporphyrins, because
porphyrins form complexes with high–molecular­
weight proteins such as albumin, making them
poorly dialyzable.11 In addition, iron has an
important role in the development of porphyria
cutanea tarda as shown by elevated serum iron
and serum ferritin and its liver stores in these
patients.2,8 It decreases the enzymatic activity of
uroporphyrinogen decarboxylase through induction
of 5-aminolevulinate synthase, a regulatory 
enzyme in heme biosynthesis.11 In addition, it also
stimulates oxidation of porphyrinogen precursors
into porphyrins.8 Serum aluminum is also believed
to be a contributing element in the pathogenesis
of porphyria cutanea tarda.10 
Although the origin of  pseudoporphyria 
development is not known, excessive ultraviolet
exposure, photoactive drugs, aluminum hydroxide,
and erythropoietin have been suggested as 
causal factors in inducing the symptoms of 
pseudoporphyria.18 Furthermore, hemodialysis
patients are more vulnerable to free radical injury
due to reduced glutathione, an antioxidant, in
plasma.11 
Treatment 
Preventive strategies include avoidance of
environmental triggers (alcohol, iron, and estrogens)
as well as sun avoidance and sun protection by using
broad-spectrum physical barriers which are key in
the management of porphyria cutanea tarda and
pseudoporphyria.8,10 As iron overload can aggravate 
the condition, the goal of treatment is to decrease
the serum ferritin levels to the lower limit of normal
range.44 Therapeutic small volume phlebotomy (50
mL to 100 mL) performed once or twice weekly
has been successful in inducing the remission after
8 months of therapy.11 The use of erythropoietin
therapy in conjunction with phlebotomies has
been effective in mobilizing hepatic iron stores.3 
Deferoxamine, an iron chelator, may be helpful
but it is not suitable for long-term use because of
side effects.3 Furthermore, because the standard
hemodialysis does not eliminate uroporphyrins well,
dialysis using high-flow dialyzer with polysulphate
is used as it can decrease the porphyrin levels by
up to 37%, although this is not enough to induce
clinical remission.2,3 Antimalarial drugs such
as chloroquine or hydroxychloroquine enhance
the solubility of porphyrins thereby facilitating
the urinary excretion, but this therapy has been
unsuccessful in anuric patients.8 Plasmapheresis
and plasma exchange have demonstrated limited
success in eliminating porphyrins because they
are not used often due to high costs.2,3 Refractory
patients have exhibited complete cure following
kidney transplantation.8 
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Withdrawal  o f  culpr i t  photosens i t iz ing  
medications is crucial in managing pseudoporphyria.8 
Treatment with N-acetylcysteine has demonstrated
complete resolution of pseudoporphyria symptoms
although this may take months. There may be
recurrence of symptoms after discontinuing the
medication.8 
GADOLINIUM-INDUCED SYSTEMIC 
FIBROSIS 
Clinical Presentation 
Nephrogenic systemic fibrosis is a chronic
progressive illness that occurs after exposure to
gadolinium-based contrast agents and is typically
found in patients of ESRD, including those on
dialysis.45,46 It was first identified in 1997 as a
scleromyxedema-like skin disorder in patients with
renal insufficiency and was named nephrogenic
fibrosing dermopathy.47,48Afterwards, when the
involvement of multiple tissues other than skin was
observed (skeletal muscles, joints, myocardium,
kidneys, and testes) it was renamed as nephrogenic
systemic fibrosis.49,50 This disease has no racial or
sex predisposition as it affects men and women
equally.9,51 The reported prevalence of nephrogenic
systemic fibrosis among hemodialysis patients
is up to 18%.49 It has also been documented in
individuals with chronic kidney disease stages 3
and 4 and acute kidney failure, as well as in those
with kidney transplants.51 
Clinically,  the symptoms of nephrogenic 
systemic fibrosis may appear from the day of
exposure to gadolinium to a number of months
later.52,53 The condition presents as hardening
and thickening of the skin along with brawny
hyperpigmentation, preferentially affecting the
extremities symmetrically.49,51 The skin lesions
commonly begin on distal lower limbs with the
involvement of talocalcaneal joints which extend
upwards to the center of thighs.49,53 In the upper
extremities, it produces skin changes which ascend
from the wrist to the middle upper arms, commonly
sparing the neck and face.53 Initially, patients
may complain of itching or burning sensation
associated with cutaneous erythema and edema.52 
As the disease advances, thin fixed plaques which
are hypopigmented or red to violaceous in color
may appear on the extremities having reticular
pattern.49,52 There may be hypopigmented pink or
skin colored macules and papules which ultimately
combine to form patches and plaques.49,52 The
affected skin becomes significantly indurated and
fibrotic acquiring a woody texture.52,53 Later in the
course, skin resembles peau d’orange (follicular
dimpling) and the patients may have epidermal
atrophy and hyperkeratosis with scaling.49,53 The
scleral plaques have also been noted with eye
involvement (Figure 13).50,54,55 
Patients usually develop flexion contractures
of the joints within days or weeks, which lead
to restriction of movement with consequent
disability.50 Nephrogenic systemic fibrosis also
affects diaphragm resulting in respiratory failure,
which may lead to death.53 
Pathophysiology 
Gadolinium-based contrast agents are almost
exclusively excreted by the kidneys with over 95%
of administered dose cleared within 24 hours.50 
In individuals with normal kidney function, the
half-life of gadolinium-based contrast agents is
approximately 2 hours, which is prolonged to 30
hours or more in patients with kidney failure; thus,
Figure 13. Nephrogenic systemic fibrosis (reprinted with 
permission50,55). 
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increasing the duration of gadolinium exposure.48-50 
During this time, gadolinium which is normally
chelated when administered as a contrast agent
may dissociate from its complex and deposit
in tissues. This process is further enhanced by
metabolic acidosis, pro-inflammatory conditions,
and elevated ion levels (calcium, zinc, copper,
and iron) through transmetallation.13,49,53 This is
supported by detection of gadolinium deposits in
the skin of affected patients.53 Even though multiple
repeated exposure of gadolinium increases the risk
of developing nephrogenic systemic fibrosis, this
disease can develop even after a single dose of
gadolinium.49,53 Once the gadolinium is deposited
in tissues, it is phagocytized by macrophages which
leads to recruitment of circulating fibrocytes positive
for CD34 and procollagen-I, considered as the main
event in the mechanism of nephrogenic systemic
fibrosis.9,13,49 These fibrocytes then differentiate
into dermal fibroblast-like cells, which produce
large amounts of sulphated glycosaminoglycans­
inducing fibrosis.13 Transforming growth factor-β
and factor XIIIa+ activated dendritic cells have also
been shown to promote fibrosis in nephrogenic
systemic fibrosis.11,13 Other risk factors which may
exacerbate the condition include inflammatory
states (infection, malignancy, recent surgery, and
thrombosis), hyperphosphatemia, hypothyroidism,
parathyroid hormone, and the use of high-
dose erythropoietin therapy and exogenous 
iron.49,53 
Treatment 
The prevention of nephrogenic systemic fibrosis
is the best approach, since at present, there is no
established treatment for this debilitating disorder.53 
As this disease occurs solely in patients with kidney
failure, it is suggested that kidney function be
determined before using gadolinium-based contrast
agents either by history or laboratory testing for
measurement of glomerular filtration rate.53,54 
Additionally, these agents should be avoided
in patients with severe acute or chronic kidney
failure with a glomerular filtration rate less than
30 mL/min/1.73 m2 and in those with hepatorenal
syndrome or perioperative liver transplantation
period.53,54 Alternative imaging techniques should
be considered until and unless there is a true
indication for gadolinium-based contrast agents.50,54 
The use of lowest possible dose and avoiding
repeated exposure to gadolinium contrast agents is
suggested.50 The immediate hemodialysis preferably
done in less than 2 hours following gadolinium
exposure is recommended in patients with chronic
kidney disease which is effective in eliminating
about 93% of the administered gadolinium after
2 sessions.50,54 It is also suggested that exogenous
iron therapy should be withheld 1 week before
elective magnetic resonance imaging, as well as
the erythropoiesis-stimulating agents.50,53 
Once nephrogenic systemic fibrosis is developed,
the major therapeutic target is to recover the kidney
function, which might happen spontaneously
in patients with acute kidney failure, but in
cases of chronic kidney failure, it needs kidney
transplantation.53,54 Various treatment options have
been used including topical and oral corticosteroids,
selective H2 blockers such as cimetidine, ranitidine,
cyclosporine, and thalidomide.49 Thalidomide
has been useful in improving the very early skin
changes but remained ineffective in the advanced
stages of the disease.52 Ultraviolet A phototherapy,
extracorporeal photopheresis, plasmapheresis, and
sodium thiosulphate have demonstrated variable
efficacy in the treatment of nephrogenic systemic
fibrosis.49 Improvement in skin changes and joint
contractures has been seen with the use of imatinib
mesylate, an antifibrotic which acts by inhibiting
dermal fibroblast synthesis of fibronectin and type
I collagen and also reduces the extracellular matrix
production.50,52 In addition, physiotherapy and
pain control are also beneficial in patients with
nephrogenic systemic fibrosis.53,54,56 
CONCLUSIONS 
Dermatologic disorders are frequently seen in
patients with ESRD, which may increase with
increased duration and severity of the underlying
kidney disease. These dermatological disorders
could be potentiated by using some medications
such as warfarin and erythropoietin. These disorders
have a negative impact on patient’s physical and
mental health, rendering them a low quality of
life. Proper evaluation and management of these
dermatologic disorders may reduce the associated
morbidity and improve the quality of life in these
patients. 
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